We focus on breast cancer because (i) previous in vitro evidence indicated that CIRBP could modulate the tumoral properties of MDA-MB-231 breast cancer cells (Chang et al. 2016), (ii) immunohistochemistry (IHC) analysis pointed to the presence of CIRBP in the cytoplasm of cells from breast cancer patients (Artero-Castro et al. 2009), and (iii) the large number of samples present in databases compared to other tumor types allows for higher statistical relevance. The gene discussed is CIRBP; the disease is breast carcinoma.